Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 12, 1998, Pages 1195-1200

  Charalambous, Dora ^b   Skinner, Stewart A ^b   O'Brien, Paul E ^a  

^a ALFRED HOSPITAL   (Australia)

^b NONE

Author keywords

Colon cancer; Prostaglandin; Rat; Sulindac

Indexed keywords

PROSTAGLANDIN E; SULINDAC;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GARDNER SYNDROME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT;

EID: 0032417630     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.1998.01779.x     Document Type: Article

References (30)

1. DuBois RN. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. Gastroenterology 1995; 108: 1310-14.
2. Labayle D, Fischer D, Vielh P et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-9.
3. Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993; 328: 1313-16.
4. Gonzaga RA, Lima FR, Carneiro S, Maciel J, Amarante M. Sulindac treatment for Familial Polyposis Coli. Lancet 1985; i: 751.
5. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with Familial Adenomatous Polyposis. Br. J. Surg. 1993; 80: 1618-19.
6. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonie polyposis. Ann. Intern. Med. 1991; 115: 952-4.
7. Schussheim A, Gold DM, Levine JJ. Sulindac-induced regression of adenomatous colonie polyps in a child with a history of hepatoblastoma. J. Pediatr. Gastroenterol. Nutr. 1993; 17: 445-8.
8. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J. Surg. Ontol. 1983; 24: 83-7.
9. Waddell WR, Ganser GF, Cerise EJ. Sulindac for polyposis of the colon. Am. J. Surg. 1989; 157: 175-9.
10. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993; 122: 518-23.
11. Nugent KP, Spigelman AD, Phillips RKS. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis. Colon Rectum 1996; 39: 659-62.
12. Boolbol SK, Dannenberg AJ, Chadburn A et al. Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996; 56: 2256-60.
13. Piazza GA, Alberts DS, Hixson LJ et al. Sulindac sulphone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997; 57: 2909-15.
14. Rao CV, Rivenson A, Simi B et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res. 1995; 55: 1464-72.
15. Charalambous D, O'Brien PE. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J. Gastroenterol. Hepatol. 1996; 11: 307-10.
16. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett. 1987; 37: 147-51.
17. Piazza GA, Rahn AK, Finn TS et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res. 1997; 57: 2452-9.
18. Schnitzler M, Dwight T, Robinson BG. Sulindac increases the expression of APC mRNA in malignant colonie epithelial cells: An in vitro study. Gut 1996; 38: 707-13.
19. Metzger U, Meier J, Uhlschmid G, Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis. Colon Rectum 1984; 27: 366-9.
20. Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumours in the rat. Arch. Surg. 1991; 126: 1094-6.
21. 2 in bile acid-caused promotion of colon carcinogenesis and anti-promotion by the cyclooxygenase inhibitor indomethacin. Jpn J. Cancer Res. 1987; 78: 791-8.
22. Craven PA, Thornburg K, DeRubertis FR. Sustained increase in the proliferation of rat colonic mucosa during chronic treatment with aspirin. Gastroenterology 1988; 94: 567-75.
23. Ligumsky M, Golanska EM, Hansen DG, Kauffman GL. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 1983; 84: 756-61.
24. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992; 13: 1019-23.
25. Van Arman CG, Risley EA, Nuss GW, Hucker HB, Duggan DE. Pharmacology of sulindac. In: Huskisson EC, Franchimont P, eds. CLINORIL in the Treatment of Rheumatic Disorders. New York: Raven Press, 1976; 9-36.
26. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
27. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonie tumours. Gastroenterology 1996; 110: 1259-62.
28. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J. Biol. Chem. 1993; 268: 6610-14.
29. Jain RK. Barriers to drug delivery in solid tumours. Sci. Am. 1994; 271: 58-65.
30. Hayles CD, Andrews FJ, O'Brien PE. Tiaprofenic acid inhibits mucosal prostaglandin E: levels without delaying experimental gastric ulcer healing. J. Gastroenterol. Hepatol. 1998; 13: 572-8.